Journal Mobile Options
Table of Contents
Vol. 68, No. 3, 2003
Issue release date: July 2003
Pharmacology 2003;68:121–130

Preservation of Endothelial Function by the HMG-CoA Reductase Inhibitor Fluvastatin through Its Lipid-Lowering Independent Antioxidant Properties in Atherosclerotic Rabbits

Mitani H. · Egashira K. · Ohashi N. · Yoshikawa M. · Niwa S. · Nonomura K. · Nakashima A. · Kimura M.
aResearch Division, Tsukuba Research Institute, Novartis Pharma KK, Tsukuba, bDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, and cDepartment of Drug Metabolism and Pharmacokinetics, Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Recent evidence suggests that the beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on entothelial function and cardiovascular ischemic events may be attributed not only to their lipid-lowering effects but also to cholesterol-lowering independent (direct) effects on the atherosclerotic vessel wall. This study was designed to test the hypothesis that fluvastatin (Flu) preserves the endothelial function by its cholesterol-lowering independent actions. Rabbits were fed a 0.5% high-cholesterol (HC) diet for 12 weeks (progression phase) and then fed the HC diet either containing or not containing Flu 2 mg/kg/day for an additional 8 weeks (treatment phase). Rabbits fed a normal diet were used as controls. Plasma total and low-density lipoprotein cholesterol concentrations did not differ during the treatment phase: Endothelium-dependent/NO-mediated relaxation (acetylcholine and A23187) was impaired in the HC diet group, whereas it was preserved in the HC plus Flu treatment group. The endothelium-independent relaxation (sodium nitroprusside) was similar between the three groups. Interestingly, aortic oxidative stress (lipid peroxides and isoprostane F-III contents) and NADPH oxidase component (p22phox and gp91phox) mRNA expression were increased in the HC group but not in the HC plus Flu group. The A23187-induced nitric oxide production from the aorta was increased in both HC and HC plus Flu groups. There was no significant difference in tissue endothelial-type nitric oxide synthase mRNA expression. Plaque area and intimal thickening of the aorta were significantly lowered in the HC plus Flu group. Flu treatment preserved the endothelial function associated with the decrease in markers of oxidative stress in this experiment. These beneficial endothelial effects of Flu are likely to occur independently of plasma lipid concentrations and to be mediated by its antioxidant action.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Wever R, Stroes E, Rabelink TJ: Nitric oxide and hypercholesterolemia: A matter of oxidation and reduction? Atherosclerosis 1998;137(suppl):51–60.
  2. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153–2157.
  3. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS; Sessa WC: Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731–736.
  4. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A: Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998;18:1456–1464.
  5. Kitamoto S, Egashira K, Kataoka C, Koyanagi M, Katoh M, Shimokawa H, Morishita R, Kaneda Y, Sueishi K, Takeshita A: Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation 2000;102:806–812.
  6. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A: Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 200;102:2243–2248.
  7. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, Tomita H, Shimokawa H, Takeshita A: Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 2000;35:86–90.
  8. Patel RP, Levonen A, Crawford JH, Darley-Usmar VM: Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc Res 2000;47:465–474.
  9. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546–2551.
  10. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, Takeshita A: Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 2000;18:1795–1800.
  11. Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, Shimokawa H, Takeshita A: Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999;34:546–551.
  12. Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 2000;33(suppl):85–97.
  13. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519–2524.
  14. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study. Circulation 1998;98:211–216.
  15. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
  16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–1307.
  17. Herd JA: The Lipoprotein and Coronary Atherosclerosis study (LCAS): Lipid and metabolic factors related to atheroma and clinical events. Am J Med 1998;104(6A):24S–49S.
  18. Mitani H, Kimura M: Fluvastatin, HMG-CoA reductase inhibitor. Antiatherogenic profiles through its lipid-lowering-dependent and -independent actions. Cardiovasc Drug Rev 2000;18:284–303.
  19. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG-CoA reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc Res 2001;49:281–287.
  20. Giroux LM, Davignon J, Naruszewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335–338.
  21. Rikitake Y, Kawashima S, Takeshita Y, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001:154:87–96.
  22. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects – the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001;155:347–357.
  23. Yokoyama M, Inoue N, Kawashima S: Role of the vascular NADH/NADPH oxidase system in atherosclerosis. Ann N Y Acad Sci 2000;902:241–247; discussion 247–248.
  24. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M: Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998;97:135–137.
  25. Patrono C, FitzGerald GA: Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309–2315.
  26. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T: An in vitro study of the hydroxyl radical scavening property of fluvastatin, an HMG-CoA reductase inhibitor. Chem Pharm Bull (Tokyo) 1999;47:1010–1012.
  27. Yamamoto A, Hoshi K, Ichihara K: Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 1998;361:143–149.
  28. Yasuhara M, Suzumura K, Tanaka K, Takahashi M, Aoki S, Odawara A, Narita H, Suzuki T: Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 2000;23:570–574.
  29. Suzumura K, Odawara A, Yasuhara M, Tanaka K, Narita H, Suzuki T: In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation. Biol Pharm Bull 1999;22:971–974.
  30. Adachi T, Cohen RA: Decreased aortic glutathione levels may contribute to impaired nitric oxide-induced relaxation in hypercholesterolaemia. Br J Pharmacol 2000:129:1014–1020.
  31. Osborne JA, Siegman MJ, Sedar AW, Mooers SU, Lefer AM: Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am J Physiol 1989;256:C591–C597.
  32. Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, Ishikawa J, Totsuka T, Sakurai I; Hayashi S: Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 2000;35:136–144.
  33. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S: Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996;119:1269–1275.
  34. Shiomi M, Shiraishi M, Yata T, Ito T: Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels: In vivo study using low density lipoprotein receptor deficient Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung 1994;44:1154–1156.
  35. Ohashi N, Yoshikawa M: Rapid and sensitive quantification of 8-isoprostaglandin F2alpha in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;746:17–24.
  36. Jones SA, O’Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT: Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996;271:H1626–H1634.
  37. Kanazawa K, Kawashima S, Mikami S, Miwa Y, Hirata K, Suematsu M, Hayashi Y, Itoh H, Yokoyama M: Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am J Pathol 1996;148:1949–1956.
  38. Pervin S, Singh R, Rosenfeld ME, Navab M, Chaudhuri G, Nathan L: Estradiol suppresses MCP-1 expression in vivo: Implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1575–1582.
  39. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000:56:225–229.
  40. Tse FL, Jaffe JM, Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992;32:630–638.
  41. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR, Lerman A: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122–128.
  42. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000;67:863–876.
  43. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA: Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 1996;93:8745–8749.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50